Searching the RRID Resource Information Network
Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.
SciCrunch Registry is a curated repository of scientific resources, with a focus on biomedical resources, including tools, databases, and core facilities - visit SciCrunch to register your resource.
| Resource Name | Proper Citation | Abbreviations | Resource Type |
Description |
Keywords | Resource Relationships | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
DMI Resource Report Resource Website |
DMI (RRID:SCR_008599) | DMI | software resource | Computational tool developed to help identify cancer-associated ''driver'' mutations from ''passenger'' ones in a cancer genome. | is listed by: OMICtools | Cancer | OMICS_00148 | SCR_008599 | SciCrunch Registry | Driver Mutation Identification | 2026-10-17 01:27:04 | 0 | ||||||||
|
Oklahoma Medical Research Foundation Resource Report Resource Website 50+ mentions |
Oklahoma Medical Research Foundation (RRID:SCR_005287) | OMRF | institution | A biomedical research institute that aims to understand and develop more effective treatments for human disease, focusing on critical research areas such as heart disease, cancer, lupus and Alzheimer's disease. | human disease, cardiovascular disease, cancer, lupus, alzheimer’s disease, treatment, biomedical research institute |
is parent organization of: C. elegans Gene Knockout Consortium is parent organization of: Oklahoma Medical Research Foundation OMRF Clinical Genomics Center Core Facility |
Heart disease, Cancer, Lupus, Alzheimer's disease | Public | grid.274264.1, ISNI: 0000 0000 8527 6890, Wikidata: Q7082264, nlx_144327, Crossref funder ID: 100008907 | https://ror.org/035z6xf33 | SCR_005287 | SciCrunch Registry | 2026-10-17 01:26:16 | 61 | ||||||
|
University of Rochester Program for Brain Tumors and Spinal Tumors Resource Report Resource Website |
University of Rochester Program for Brain Tumors and Spinal Tumors (RRID:SCR_005343) | URMC Program for Brain and Spinal Tumors, | biomaterial supply resource, brain bank, material resource, tissue bank | Collaborative neuro-oncology research program with a tissue repository (tumor bank) containing a wide range of clinical specimens, which they make available to researchers in order to study the effects of new drugs on a large number and wide range of tumor specimens. They provide highly coordinated, complex care in neurosurgery, radiation oncology, medical oncology, and neurology to patients afflicted with tumors of the brain and spine by combining the newest technologies and treatments available anywhere in the world. The program is formed from a multidisciplinary group with a goal of helping patients navigate the complex issues surrounding brain and spinal cancer care. The researchers are working to increase the number of targets that could be considered for anti-angiogenesis therapy. Many of their studies focus on the blood vessel cells (endothelial cells) themselves, which, unlike tumor cells, rarely mutate and so might be less likely to become resistant to therapy and are also more easily reached through the bloodstream. Their researchers are also attempting to better understand the changes in the blood-brain barrier (BBB) that are associated with fluid accumulation and brain swelling (edema) in neuro-oncology patients. Normal brain tissue is shielded from the rest of the body by the BBB. This barrier is composed of very tight blood vessels that prevent most substances from entering the brain. Brain tumors have a leaky BBB ����?? this feature can be used to identify tumors on MRI scans. They have identified specific molecules that appear to be associated with the leaky, abnormal vessels while the normal blood vessels with intact BBB produce these molecules at very low levels or not at all. Inhibiting the function of these molecules may help control or prevent disruption of the BBB and limit cerebral edema in brain tumor patients, as well as patients suffering from stroke or traumatic brain injury. | brain tissue, brain, tissue, spine, spinal tumor, brain tumor, tumor, cancer, normal control, clinical trial, treatment, acoustic neuroma, anaplastic astrocytoma, brain metastases, brain stem glioma, chordoma, cns lymphoma, craniopharyngioma, ependymoma, gliomatosis cerebri, glioblastoma, low grade glioma, meningioma, medulloblastoma, oligodendroglioma, pineal tumor, pilocytic astrocytoma, pituitary adenoma, premature neuroectodermal tumor, oncology, neurooncology, stroke, traumatic brain injury, cerebral edema | is listed by: One Mind Biospecimen Bank Listing | Tumor, Brain tumor, Cancer, Spinal tumor, Normal control | Available to researchers - not clear if internally or if provide specimens to the public | nlx_144398 | http://www.urmc.rochester.edu/neurosurgery/neurooncology/overview/research/ | SCR_005343 | SciCrunch Registry | University of Rochester Brain Tumor and Spinal Tumor Program | 2026-10-17 01:26:21 | 0 | |||||
|
UCSF Helen Diller Family Comprehensive Cancer Center Biostatistics Core Resource Report Resource Website |
UCSF Helen Diller Family Comprehensive Cancer Center Biostatistics Core (RRID:SCR_005701) | UCSF Helen Diller Family Comprehensive Cancer Center Biostatistics Core | analysis service resource, data analysis service, production service resource, service resource, training service resource | The Biostatistics Core provides statistical support for cancer-related research at UCSF, focusing particulary on applications in clinical trials and population studies. The Computational Biology Core supports applications to genomics, genetics and molecular biology. Core faculty have expertise in study design, protocol and proposal development and review, data analysis, and publication of results. Support for Cancer Center investigators participating in established Site Committees is typically handled by the faculty member assigned to that committee. Other requests can be directed to the consulting service request page maintained by the UCSF Clinical & Translational Science Institute (CTSI). These requests will then be assigned to a Core faculty member. Basic consulting services are generally provided free of charge to Cancer Center Members. Members requiring frequent assistance are encouraged to provide regular salary support to a Core statistician when possible to support more extensive requests and for long-term projects. Services: * Study Design * Guidance on Study Conduct * Data Analysis and Reporting of Study Results * Teaching resources |
has parent organization: UCSF Helen Diller Family Comprehensive Cancer Center is parent organization of: EGAN: Exploratory Gene Association Networks |
Cancer | nlx_149150 | http://cancer.ucsf.edu/cores/biostatistics/index.php | SCR_005701 | SciCrunch Registry | UCSF Helen Diller Family Comprehensive Cancer Center Biostatistics Computational Biology Core, UCSF Helen Diller Family Comprehensive Cancer Center Biostatistics and Computational Biology Core | 2026-10-17 01:26:25 | 0 | |||||||
|
Terry Fox Foundation Resource Report Resource Website 1+ mentions |
Terry Fox Foundation (RRID:SCR_005873) | TFF | institution | The Terry Fox Foundation is responsible for supporting close to $20 million in discovery based research each year in Canada - all monies raised outside Canada must be distributed to (a) an institute approved by the Foundation and its advisors or (b) remitted to Canada. The Terry Fox Research Institute (TFRI) is a recipient of TFF funding for translational research. TFRI is an exciting new initiative whose goal is to translate rapidly today''s best science into better cancer treatment and diagnosis for all Canadians. The Institute will bring scientists and clinicians together across the country into a functionally integrated, geographically dispersed Institute with nodes in several provinces. Terry Fox was diagnosed with osteogenic sarcoma (bone cancer) in his right leg in 1977 and had his leg amputated 15 cm (six inches) above the knee. While in hospital, Terry was so overcome by the suffering of other cancer patients that he decided to run across Canada to raise money for cancer research. He called his journey the Marathon of Hope. Terry''s Marathon of Hope took place in 1980 with the simple objective of informing Canadians of the importance of finding a cure for cancer. With fierce determination, he ran an average of 42 kilometres (26 miles) every day for 143 days. Terry was forced to end his run on September 1, 1980 when the cancer spread to his lungs. By February 1, 1981, Terry''s dream of raising $1 for every Canadian was realized - the Terry Fox Marathon of Hope fund totaled $24.17 million. Terry died in June 1981. On May 26, 1988, The Terry Fox Run became a Trust, independent from the Canadian Cancer Society, and received tax-exempt charitable registration as a public foundation. In addition to our signature and long-standing National Terry Fox Run Day in September of each year, The Terry Fox Foundation is proud to include in its events portfolio The National School Run Day. The Foundation recognizes the duality of its mandate. Not only does it raise money for research, but it also continues to share the story of Terry Fox. The Terry Fox Foundation strives to maintain the heroic effort and integrity that Terry embodied. It is a grassroots organization that does not allow the Terry Fox name or likeness to be commercialized or conjoined with other worthy causes. To date, over $600 million has been raised worldwide for cancer research in Terry''s name. | research, cancer | is parent organization of: Terry Fox Research Institute | Cancer | ISNI: 0000 0004 5907 4557, Crossref funder ID: 501100002655, nlx_149429, grid.453650.1 | https://ror.org/05vd00053 | SCR_005873 | SciCrunch Registry | 2026-10-17 01:26:28 | 5 | |||||||
|
Research Accelerator Resource Report Resource Website 1+ mentions |
Research Accelerator (RRID:SCR_006051) | UCSD Research Accelerator | community building portal, data or information resource, database, portal, service resource | Software platform that allows researchers to easily collaborate on research and share reagents, antibodies, cell lines and more. It is designed to increase scientific collaboration across disciplines and geographical boundaries. Among the institutions now using the platform include Yale University, U of Pennsylvania, U of Chicago, Washington U, Cambridge University, University College London. The platform is licensed to select institutions. ResearchAccelerator.org allows researchers to form targeted, data driven collaborations. Researchers can search for data based on gene, disease and pathway, and they can post data which would otherwise be orphaned. The resulting collaborations, which are likely to be transdisciplinary, can greatly amplify impact and research productivity. | collaboration, transdisciplinary research, gene, pathway, disease, cell line, data, human sample, laboratory protocol, medical device, equipment, resource, reagent, research project, transgenic animal, knock out animal, validated antibody, yale keck proteomics assay, allergy, immunology, bone, joint, orthopedic, cancer, cardiovascular, gastroenterology, infectious disease, neurologic disease, organ transplantation, psychiatric disease, reproductive disease, vascular disease, sharing, material resource |
is used by: University College London; London; United Kingdom is used by: University of Cambridge; Cambridge; United Kingdom is used by: Washington University in St. Louis; Missouri; USA is used by: University of Chicago; Illinois; USA is used by: University of Pennsylvania; Philadelphia; USA is used by: Yale University; Connecticut; USA has parent organization: University of California at San Diego; California; USA |
Allergy, Immunology, Bone, Joint, Orthopedic, Cancer, Cardiovascular, Gastroenterology, Infectious Disease, Neurologic disease, Organ Transplantation, Psychiatric disease, Reproductive disease, Vascular disease | The community can contribute to this resource | nlx_151451 | SCR_006051 | SciCrunch Registry | ResearchAccelerator.org, ResearchAccelerator | 2026-10-17 01:26:27 | 1 | ||||||
|
ACTREC - Advanced Centre for Treatment Research and Education in Cancer Resource Report Resource Website 1+ mentions |
ACTREC - Advanced Centre for Treatment Research and Education in Cancer (RRID:SCR_006021) | ACTREC | institution | The Advanced Centre for Treatment, Research and Education in Cancer (ACTREC) is the new state-of-the-art R&D satellite of the Tata Memorial Centre (TMC), which also includes under its umbrella the Tata Memorial Hospital (TMH), the largest cancer hospital in Asia. ACTREC has the mandate to function as a national centre for treatment, research and education in cancer. TMC is an autonomous grant-in-aid institution of the Department of Atomic Energy (DAE), Government of India. It is registered under the Societies Registration Act (1860) and the Bombay Public Trust Act (1950). Its Governing Council is headed by the Chairman, Atomic Energy Commission, Government of India. ACTREC comprises of 2 arms - one for basic research and another for clinical research. The basic research building was inaugurated in March 2002 at the new site of ACTREC in Kharghar, Navi Mumbai. In August 2002, the Cancer Research Institute (CRI) shifted in toto from its Parel campus in Mumbai to serve as the basic research arm of ACTREC. The clinical research arm of ACTREC comprising of the Clinical Research Centre (CRC) has become functional from March 2005. ACTREC also has a 50-bed hospital fully equipped with state-of-the-art diagnostic and therapeutic facilities. Research investigations at CRI currently focus on molecular mechanisms responsible for causation of major human cancers relevant to India. It is envisaged that in the future, ACTREC will play a greater role in drug development and emerging therapies for treatment and prevention of cancer. | cancer, basic research, clinical research, drug development, therapy, treatment, prevention, research, education | is parent organization of: HIstome: The Histone Infobase | Cancer | Crossref funder ID: 501100007179, ISNI: 0000 0004 1766 7522, grid.410869.2, nlx_151418 | https://ror.org/05b9pgt88 | SCR_006021 | SciCrunch Registry | Advanced Centre for Treatment Research and Education in Cancer | 2026-10-17 01:26:25 | 2 | ||||||
|
Longevity Foundation Resource Report Resource Website |
Longevity Foundation (RRID:SCR_006338) | Longevity Foundation | funding resource | Funding resource that supports research into A-T (Ataxia Telangiectasia) and other debilitating, degenerative diseases plaguing human kind, including cancer and neuro-degeneration associated with auto-immunity and aging. Researchers share their findings and collaborate with each other. The research must lead to practical, near-term treatments and cures to receive funds. The researchers have found treatments and cures that are the first of their kind in the world. Over $850,000 in direct research grants have been made. These grants have leveraged over $9 million in research resources contributed by partner institutions. We pay the research institutions for direct costs only. We pay no administrative, indirect, or overhead costs. | grant, research | Degenerative disease, Ataxia Telangiectasia, Neurodegeneration, Autoimmunity, Inflammation, Premature aging, Aging, Cancer | nlx_152041 | SCR_006338 | SciCrunch Registry | 2026-10-17 01:26:34 | 0 | |||||||||
|
CGARS Resource Report Resource Website |
CGARS (RRID:SCR_006404) | CGARS | software resource | Software package to dissect random from non-random patterns in copy number data and thereby to assess significantly enriched somatic copy number aberrations (SCNA) across a set of tumor specimens or cell lines. | genome, analysis |
is listed by: OMICtools has parent organization: University of Cologne; Cologne; Germany |
Cancer | PMID:24413525 | GNU General Public License, v3 or later | OMICS_02210 | SCR_006404 | SciCrunch Registry | CGARS: Cancer Genome Analysis by Rank Sums, Cancer Genome Analysis by Rank Sums | 2026-10-17 01:26:41 | 0 | |||||
|
JISTIC Resource Report Resource Website 1+ mentions |
JISTIC (RRID:SCR_003482) | JISTIC | software resource | Software tool for analyzing datasets of genome-wide copy number variation to identify driver aberrations in cancer. | copy number variation, candidate gene, gene |
is listed by: OMICtools has parent organization: Columbia University; New York; USA |
Cancer | PMID:20398270 | Free, Public | OMICS_02297 | SCR_003482 | SciCrunch Registry | 2026-10-17 01:25:35 | 2 | ||||||
|
Lyonbiopole Resource Report Resource Website |
Lyonbiopole (RRID:SCR_003733) | Lyonbiopole | data or information resource, funding resource, organization portal, portal | A worldwide competitiveness cluster centered on pharmaceutical activities including the fight against human and animal infectious diseases and cancers. Designed as a tool interface and public / private approximation, the division has implemented measures to encourage collaborative R & D, help in setting up projects and find funding, increase strategic and financial partnerships for economic development and international companies, provide access to reception areas, technological shared platforms such as the Infectious Diseases Center Lyonbiop��le. It aims to strengthen the competitiveness of the sector health and the attractiveness of the Rh��ne-Alpes area, mainly on the Lyon-Grenoble axis. (adapted from the translated Wikipedia) | vaccine, diagnostic, pharmaceutical, drug, prevention, treatment | Infectious disease, Cancer | nlx_157924 | SCR_003733 | SciCrunch Registry | Lyonbiop��le, Lyon Biopole | 2026-10-17 01:25:37 | 0 | ||||||||
|
Structural Genomics Consortium Resource Report Resource Website 50+ mentions |
Structural Genomics Consortium (RRID:SCR_003890) | SGC | consortium, data or information resource, organization portal, portal | Charity registered in United Kingdom whose mission is to accelerate research in new areas of human biology and drug discovery.Not for profit, public-private partnership that carries out basic science of relevance to drug discovery whose core mandate is to determine 3D structures on large scale and cost effectively targeting human proteins of biomedical importance and proteins from human parasites that represent potential drug targets. | basic science, drug discovery, drug, structural genomics, genomics, 3d structure, protein, human parasite, drug target, structure, human protein, protocol, phylogenetic tree, histone tail, high-throughput protein crystallization, lex bubbling system, reagent, epigenetic probe, antibody, vector, plasmid, construct |
uses: Research Collaboratory for Structural Bioinformatics Protein Data Bank (RCSB PDB) uses: Addgene uses: GenBank is related to: AbbVie is related to: Canada Foundation for Innovation is related to: Canadian Institutes of Health Research is related to: Genome Canada is related to: Janssen Research and Development is related to: Ontario Ministry of Economic Development Employment and Infrastructure is related to: Pfizer Animal Genetics is related to: Wellcome Trust has parent organization: University of Oxford; Oxford; United Kingdom has parent organization: University of Toronto; Ontario; Canada |
Cancer, Diabetes, Obesity, Psychiatric disorder, Altzheimer | AbbVie ; Boehringer Ingelheim ; Canada Foundation for Innovation ; Canadian Institutes of Health Research ; Genome Canada ; GlaxoSmithKline ; Janssen ; Lilly Canada ; Novartis Research Foundation ; Ontario Ministry of Economic Development Employment and Infrastructure ; Pfizer ; Takeda ; Wellcome Trust |
Restricted | nlx_158220 | SCR_003890 | SciCrunch Registry | Structural Genomics Consortium | 2026-10-17 01:25:56 | 65 | |||||
|
Hybrigenics Resource Report Resource Website 10+ mentions |
Hybrigenics (RRID:SCR_003822) | commercial organization | A bio-pharmaceutical company with a focus on research and development of new targets & therapies against proliferative diseases. Its current development program is based on inecalcitol, a vitamin D receptor agonist being studied in three potential indications: * alone in chronic lymphocytic leukaemia * in combination with imatinib in chronic myeloid leukaemia * in prostate cancer, for use with current standards of care Hybrigenics'' research program investigates the action of enzymes called Deubiquitinating Enzymes (DUBs) in the recycling of onco-proteins and the utility of proprietary patented DUB inhibitors against various cancer indications. Hybrigenics Services, a Hybrigenics subsidiary, markets very specialized scientific services to researchers in all areas of life sciences who want to identify, validate and inhibit protein interactions in animal, plant or microbiological cells. | enzyme, proteomic, protein interaction network, protein interaction | is related to: AgedBrainSYSBIO | Lymphocytic leukaemia, Myeloid leukaemia, Prostate cancer, Cancer | nlx_158127 | SCR_003822 | SciCrunch Registry | 2026-10-17 01:25:40 | 16 | |||||||||
|
Amorfix Resource Report Resource Website 1+ mentions |
Amorfix (RRID:SCR_003783) | AMF | commercial organization | Product development company focused on therapeutic products and diagnostic devices targeting misfolded protein diseases. On July, 2015 the company name was changed to ProMIS Neurosciences, Inc. | diagnostic, therapy, alzheimer, protein, misfolded protein disease | Alzheimer's disease, Amyotrophic Lateral Sclerosis, Cancer | Crossref funder ID: 100007611, nlx_158072, grid.422608.a | https://ror.org/045rtab03 | SCR_003783 | SciCrunch Registry | Amorfix Life Science, Amorfix Life Sciences Ltd., Amorfix Life Sciences, ProMIS Neurosciences | 2026-10-17 01:25:54 | 2 | |||||||
|
ChemoCentryx Resource Report Resource Website 10+ mentions |
ChemoCentryx (RRID:SCR_003976) | commercial organization | A biopharmaceutical company focused exclusively on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. Each drug candidate is a small molecule designed to target a specific chemokine or chemo-attractant receptor, thereby blocking the inflammatory response driven by that particular chemokine while leaving the rest of the immune system unaffected., THIS RESOURCE IS NO LONGER IN SERVICE. Documented on September 16,2025. | biopharmaceutical, oral administration, medicine, small molecule, chemokine, chemo-attractant receptor, clinical, drug, oral drug | is related to: Kidney Health Initiative | Autoimmune disease, Inflammatory disorder, Cancer | THIS RESOURCE IS NO LONGER IN SERVICE | nlx_158383, grid.452218.8, ISNI: 0000 0004 0408 7502 | https://ror.org/04gp12571 | SCR_003976 | SciCrunch Registry | ChemoCentryx Inc, ChemoCentryx Inc. | 2026-10-17 01:25:58 | 43 | ||||||
|
C. R. Bard Resource Report Resource Website 1+ mentions |
C. R. Bard (RRID:SCR_003975) | BARD, BCR | commercial organization | A multinational developer, manufacturer, and marketer of medical technologies specializing in the manufacture of vascular, urology, oncology and surgical specialty products. BARD pioneered the development of single-patient-use medical products for hospital procedures; today BARD is dedicated to pursuing technological innovations that offer superior clinical benefits while helping to reduce overall costs. Bard is perhaps best known for having introduced the Foley catheter. (Adapted from Wikipedia) | medical equipment, vascular, urology, oncology, surgical, medical technology, medical, clinical | is related to: Kidney Health Initiative | Cancer | nlx_158382 | SCR_003975 | SciCrunch Registry | C. R. Bard Inc., C.R. Bard Inc., C. R. Bard Inc, CR Bard, C.R. Bard Inc, C.R. Bard, CR Bard Inc. | 2026-10-17 01:26:07 | 2 | |||||||
|
Centre for Genomics and Oncological Research Resource Report Resource Website |
Centre for Genomics and Oncological Research (RRID:SCR_003920) | GENYO | institution | Center for excellence research in genomic medicine, focusing on the comprehensive study and understanding of the genetic basis of human diseases in general, placing special emphasis on cancer and its genetic disorders related to inheritance. GENYO was created as a multidisciplinary research space, where different professionals from the healthcare, university and business areas interact, making it possible to generate new systems to diagnose, prevent and treat diseases based on the joint and coordinated application of first-rate knowledge in the different areas of genetics. The center is the benchmark center of the Andalusian Program for Research in Clinical Genetics and Genomic Medicine, a program which, together with those of Cell Therapy and Regenerative Medicine, and Nanomedicine have the main objective of supporting and fostering translational research in Advanced Therapies. The activities performed within these three research programs are developed in coordination with the Andalusian Initiative for Advanced Therapies (IATA), an initiative of the Andalusian Government promoted by the Regional Ministries of Health and Innovation, Science and Enterprise. | genomic medicine, genomic, oncology, pharmacogenomics, inheritance, genetics |
is related to: PRECISESADS has parent organization: University of Granada; Granada; Spain has parent organization: Progress and Health Foundation; Seville; Spain is parent organization of: PRECISESADS |
Cancer, Genetic disorder | grid.470860.d, Crossref funder ID: 501100007321, ISNI: 0000 0004 4677 7069, nlx_158281 | https://ror.org/04hr99439 | SCR_003920 | SciCrunch Registry | Pfizer-University of Granada-Junta de Andaluc??a Centre for Genomics and Oncological Research (GENYO), Pfizer-University of Granada-Junta de Andaluc??a Centre for Genomics and Oncological Research | 2026-10-17 01:25:44 | 0 | ||||||
|
Institute of Cancer Research Resource Report Resource Website 10+ mentions |
Institute of Cancer Research (RRID:SCR_003912) | ICR | institution | Academic cancer research center, a postgrad college, and a charity in the United Kingdom that is making discoveries that defeat cancer. With their partners The Royal Marsden NHS Foundation Trust they form the largest comprehensive cancer center in Europe and perform high quality and original basic research and translational studies, with the aim of developing better treatments for the benefit of cancer patients worldwide. The ICR offers comprehensive, modern facilities for research and studentships supported by the Wellcome Trust, MRC, CRUK and EPSRC and the ICR''s own resources which are awarded on a competitive basis. The ICR offers postgraduate research degrees (MPhil, PhD and MD (Res)) and a modular postgraduate taught degree in oncology aimed at clinicians undertaking specialist training in the field of Clinical or Medical Oncology leading to a Postgraduate Certificate, Postgraduate Diploma or MSc in Oncology. | clinical, medical, oncology |
is related to: PREDECT has parent organization: University of London; London; United Kingdom is parent organization of: FLIGHT is parent organization of: MoKCa- Mutations of Kinases in Cancer |
Cancer | nlx_158259, grid.18886.3f, Wikidata: Q6039999, ISNI: 0000 0001 1271 4623 | https://ror.org/043jzw605 | SCR_003912 | SciCrunch Registry | The Institute of Cancer Research | 2026-10-17 01:26:06 | 12 | ||||||
|
Orion Resource Report Resource Website 10+ mentions |
Orion (RRID:SCR_003911) | Orion | commercial organization | A globally operating Finnish developer, manufacturer and marketer of human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. They are continuously developing new drugs and treatment methods. Pharmaceutical RD focuses on central nervous system drugs, oncology and critical care drugs, and Easyhaler pulmonary drugs. | pharmaceutical, drug, diagnostic test, diagnostic, central nervous system, drug, oncology, critical care, pulmonary, central nervous system drug, pulmonary drug, cancer, veterinary drug, medicine, clinical, hygiene monitoring |
is related to: MIP-DILI is related to: NEWMEDS is related to: ORBITO is related to: PREDECT |
Cancer, Asthma, Alzheimer's disease, Parkinson's disease, Breast cancer, Prostate cancer | nlx_158257 | SCR_003911 | SciCrunch Registry | Orion Corporation, Orion Pharma | 2026-10-17 01:25:42 | 34 | |||||||
|
Genentech Resource Report Resource Website 1000+ mentions |
Genentech (RRID:SCR_003997) | Genentech | commercial organization | A biotechnology corporation that uses human genetic information to discover, develop, manufacture and commercialize medicines to treat patients with serious or life-threatening medical conditions. | drug, genetic, medicine, biotechnology, oncology, immunology, tissue growth, tissue repair, neuroscience, infectious disease, microbiology, medical imaging |
is related to: Alzheimers Disease Genetics Consortium has parent organization: Roche is parent organization of: GMAP |
Infectious disease, Cancer | nlx_158417 | SCR_003997 | SciCrunch Registry | Genentech Inc, F. Hoffmann-La Roche Ltd / Genentech | 2026-10-17 01:25:46 | 3311 |
Can't find your Tool?
We recommend that you click next to the search bar to check some helpful tips on searches and refine your search firstly. Alternatively, please register your tool with the SciCrunch Registry by adding a little information to a web form, logging in will enable users to create a provisional RRID, but it not required to submit.
Welcome to the NIF Resources search. From here you can search through a compilation of resources used by NIF and see how data is organized within our community.
You are currently on the Community Resources tab looking through categories and sources that NIF has compiled. You can navigate through those categories from here or change to a different tab to execute your search through. Each tab gives a different perspective on data.
If you have an account on NIF then you can log in from here to get additional features in NIF such as Collections, Saved Searches, and managing Resources.
Here is the search term that is being executed, you can type in anything you want to search for. Some tips to help searching:
If you are logged into NIF you can add data records to your collections to create custom spreadsheets across multiple sources of data.
Here are the facets that you can filter the data by.
If you have any further questions please check out our FAQs Page to ask questions and see our tutorials. Click this button to view this tutorial again.
Welcome to the Neuroscience Information Framework Project, designed to serve the biomedical research community. NIF maintains the largest searchable collection of neuroscience data, the largest catalog of biomedical resources, and the largest ontology for neuroscience on the web. We welcome all feedback and suggestions and are actively looking for resource providers to make their resources accessible through NIF. Learn about the tools available to help you share your data and discover a dynamic inventory of Web-based neuroscience resources.
